Preclinical evaluation of nanoparticle enhanced breast cancer diagnosis and radiation therapy
von Jonas Albers
Datum der mündl. Prüfung:2021-06-22
Erschienen:2021-07-09
Betreuer:Prof. Dr. Frauke Alves
Gutachter:Prof. Dr. Dörthe Katschinski
Gutachter:Prof. Dr. Hubertus Jarry
Zum Verlinken/Zitieren:
http://dx.doi.org/10.53846/goediss-8725
Dateien
Name:PhDThesis_JonasAlbers.pdf
Size:7.42Mb
Format:PDF
Lizenzbestimmungen:
Zusammenfassung
Englisch
Triple negative breast cancer (TNBC) is an aggressive type of cancer which makes up 15-20% of all newly diagnosed cases, lacking the main target molecules for tumor specific treatment. Surgery or systemic therapy by chemotherapy are frequently used in the clinic and combined with radiation therapy to improve locoregional control in breast cancer patients after surgery. With a poor prognosis, there is a clear need to explore new treatment options for TNBC. The aim of the here presented PhD project was to evaluate the feasibility to enhance the biological effect of radiation therapy and increase tumor contrast for diagnosis by applying an in vivo microCT imaging system in combination with barium nanoparticles (BaNPs) in a pH8N8 WAP-T-NP8 mouse model for TNBC. Characterization of the BaNPs revealed strong x-ray attenuation and no toxic effects in different cancer and normal cell lines. Furthermore, irradiation of cancer cells using low energy x-rays in the keV range by a microCT resulted in a significant reduction on colony formation capability. In vitro, this low energy irradiation effect on clonogenic tumor cell survival was enhanced in the presence of BaNPs. Next, a subcutaneous lung cancer mouse model in immunodeficient mice and an orthotopic syngeneic mouse model for breast cancer was applied for further in vivo evaluation. Once the treatment plan was optimized regarding the applied x-ray doses and the frequency of irradiation, low energy radiation therapy within a classical in vivo microCT significantly reduced tumor growth or even resulted in shrinkage of the tumors without visible side effects and weight loss in comparison to untreated controls. However, the intratumoral application of BaNPs was not able to increase the irradiation effect on tumor growth kinetics. This might be in part due to inhomogeneous distribution of BaNPs within the tumor observed by microCT imaging. K-edge subtraction imaging as well as x-ray fluorescence of explanted tumor samples confirmed these findings. To localize the BaNPs in 3D to specific sites within the tumor environment and to detect morphological alterations within the tumor due to irradiation in proximity to BaNPs an ex-vivo imaging based analytic platform was established, utilizing co-registration of microCT and histology data. This imaging approach co-localized BaNPs with CD68 positive phagocytic cells and revealed a non-uniform distribution of the BaNPs within the tumor, however with no signs of locally enhanced radiation effects. Furthermore, antibody functionalized BaNPs were generated for systemic application. Analysis of biodistribution revealed that EpCAM labeled BaNPs did not reach the tumor after intra-venous administration, but accumulated in liver and spleen, demonstrated by a strong CT contrast within these organs. In summary, I showed that low energy radiation therapy by applying an in vivo microCT significantly reduced tumor volumes in comparison to untreated tumors in a syngeneic breast cancer tumor mouse model resembling TNBC. However, BaNPs while enhancing the effectiveness of irradiation on tumor cells in vitro, did not improve the irradiation effect on tumor growth in vivo.
Keywords: Radiotherapy; Computed Tomography; Breast Cancer